Households with GLP-1 users could account for 35% of food and beverage sales by 2030, up from 23% today, per Circana. Rising GLP-1 usage is reshaping grocery spending, with profound implications for foodmakers and grocers. As GLP-1s grow more accessible—thanks to microdosing, efforts to make the drugs more affordable, and the pending release of a weight-loss pill—their impact will be more deeply felt beyond food to sectors including apparel, wellness, beauty, and restaurants.
Eli Lilly became the first healthcare or pharma company to reach a $1 trillion valuation. Pharma’s entry into “the trillion-dollar club” is largely driven by success in the obesity treatment category that’s poised to reshape consumer health and wellness. However, Lilly’s particular rapid growth signals that while first-mover advantage in a high-demand disease area matters, it doesn’t guarantee staying on top. Pharma manufacturers can make up for not being first by committing to innovative drug development that drives more efficacious products, pursuing new clinical indications, and correctly anticipating market developments that may impact supply and demand.
Starting next year, Novo Nordisk and Eli Lilly will sell their weight loss shots directly to employers, cutting out pharmacy benefit managers, per Bloomberg. This move further signals drugmakers’ push into direct sales, both to consumers and employers. More businesses will likely cover obesity drugs for their workers if they can achieve greater cost control of their offered benefits. And pharma supply chain middlemen could feel mounting pressure to shift further away from the prescription drug rebate model that so many in the industry decry.
The average cost of employer-sponsored health insurance is expected to surpass $18,500 per US worker in 2026, according to a Mercer survey released this week. That would represent a 6.7% jump from 2025—the largest increase in 15 years. Employers must conduct due diligence of vendors that offer healthcare cost-containment solutions to ensure the products are effective and deliver actual savings. Companies will also want to thoroughly evaluate their contracts with pharmacy benefit managers to better understand their prescription drug benefits, while limits on GLP-1 coverage, especially as upcoming oral versions and new condition approvals drive up demand.
Hours after online healthcare company Mangoceuticals claimed partnerships with Novo Nordisk and Eli Lilly to provide discounted weight loss drugs to cash-pay customers, both drugmakers denied any affiliation. As GLP-1 compounders lose their pricing edge, smaller players must resist overstating their ties to Novo and Lilly. While any healthcare provider can prescribe Lilly’s or Novo’s GLP-1s, manufacturer-set discounts won’t be made available to companies that engage in misleading marketing.
Hims & Hers said on its recent earnings call that it’s in active talks with Novo Nordisk to make Wegovy available on Hims’ platforms. Hims and Novo both have an incentive to reignite their partnership. Hims’ pricing edge in the GLP-1 market is fading, while Novo could use GLP-1 sales from Hims’ sticky customer base to make up some of the market share it has recently lost to Lilly.
Apparel companies that don’t adjust their merchandising strategies in response to rising GLP-1 usage could be stuck with up to $5 billion in excess inventory and costs, according to a report by Impact Analytics. While there are indications that rising GLP-1 adoption is increasing demand for smaller sizes, that shouldn’t be an excuse for brands to reduce plus-size production or jettison inclusive sizing. Companies that move too aggressively to reduce plus-size assortments could alienate customers and lose sales.
The number of patient appointments for weight loss drugs jumps whenever a celebrity reveals they use a GLP-1, according to Zocdoc data shared with EMARKETER. Brands that advertise access to weight loss drugs will want to develop messaging for when appointments surge. They should highlight that GLP-1s were developed to treat medical conditions (not for quick weight loss), and that companies are committed to making products available for all communities. Pharma and telehealth weight loss drug players should also provide transparent data on how many people experience which side effects when taking a GLP-1, while working with social media platforms to flag misleading content about medication efficacy and safety.
WeightWatchers launched a new menopause program with Queen Latifah as its spokesperson. This move is part of a larger strategy to expand into the clinical healthcare and prescription medication markets. To succeed against rivals like Hims & Hers and Noom, WeightWatchers needs to offer competitive pricing and secure more partnerships with major pharmaceutical companies to help raise awareness of its new focus in the growing wellness sector.
The situation: The compounded GLP-1 market isn’t dying down as quickly as previously expected. Our take: Online healthcare companies are getting crafty with how they market and sell compounded GLP-1s. Novo and Lilly will keep experimenting with legal tactics to get copycat GLP-1s off the market, but their path to victory in court is unclear. Short of the FDA stepping in—and it doesn’t seem like it will—the battle of pharma vs. compounded weight loss drug sellers will get even messier.
The news: Medicare and Medicaid could cover GLP-1s for weight loss as part of a proposed five-year government experiment, according to a report in The Washington Post. Our take: The pilot, albeit not finalized, is a significant about-face from the Trump administration—particularly its top health official, Kennedy. It could be a signal that CMS Administrator Dr. Mehmet Oz is behind the plan, since he’s a bigger proponent of the meds. Still, we’re dubious about how many health plans will commit considering GLP-1s' high costs are a top concern for most insurers.
The news: Novo Nordisk’s stock plunged over 20% on Tuesday after it cut full-year guidance, citing lower-than-expected sales growth for Wegovy, its blockbuster weight loss drug. Our take: Despite the recent slump, we think Novo is well positioned to rebound. It remains one of two dominant players in the weight loss drug space and is still posting profit growth, albeit below Wall Street expectations. With the US adult obesity rate expected to hit 50% by 2030, the market opportunity is huge. Meanwhile, regulators are likely going to make it more difficult for compounded drugs to be sold as long as brand-name forms stay off the FDA’s drug shortage list.
The news: Novo Nordisk is partnering with WeightWatchers to offer discounted Wegovy to cash-pay customers. Our take: WeightWatchers is recognizing that diet culture is being replaced by weight loss medications accessible via virtual care. To stand out from other Novo’s other telehealth partners, WeightWatchers should lean into marketing that positions the company as a pioneer weight loss brand that’s now meeting consumer demand for GLP-1s.
The news: A majority of GLP-1 weight loss drug consumers are now staying on the medications for more than a year, per an annual Prime Therapeutics analysis. The Prime study includes 5,780 people via healthcare claims over three years; the mean age was 47 and 80% were women. The final word: Adherence rates longer than a year validates the idea that prescription weight loss GLP-1s, and newer drugs on the way, are here to stay as chronic disease treatments. It shifts typical weight loss marketing from cyclical—keep your New Year’s resolution or lose weight for your wedding—to medical and consistent.
The news: Novo Nordisk is terminating its short-lived partnership with Hims & Hers. The drugmaker is accusing Hims of illegally selling knockoff versions of Wegovy, while deceptively marketing its compounded GLP-1 products. Our take: Hims will likely regret its refusal to cooperate with Novo and Eli Lilly, who have taken control of the D2C weight loss drug market.
The data: Around 2 in 5 employers and health plans will never consider covering GLP-1 drugs for obesity, according to a June 2025 report from Pharmaceutical Strategies Group. Our take: We don’t think a lack of insurance coverage for GLP-1s will lead to a market slowdown. Less generous insurance coverage of the drugs will force companies operating in the competitive cash-pay GLP-1 space to continue offering temporary discounts or lower their prices altogether.
The news: Eli Lilly said it won’t partner with telehealth companies that sell compounded weight loss drugs. Our take: Lilly’s demand may signal that it’s in a better position in the weight loss drug market than Novo to play hardball with industry partners such as Hims & Hers.
Hims & Hers expands in Europe via telehealth acquisition: Hims purchased a company with a similar business model overseas. We believe it’s a sign that Hims is losing its competitive advantage in the US weight loss drug space.
Novo Nordisk’s CEO steps down: Investor panic and a slumping stock may have been driving factors. Despite falling behind Eli Lilly in the weight loss drug market, recent moves around oral GLP-1 development put Novo in a strong position.
Powerful data and analysis on nearly every digital topic.
Become a ClientWant more marketing insights?
Sign up for EMARKETER Daily, our free newsletter.
Thanks for signing up for our newsletter!
You can read recent articles from EMARKETER here.